ArticleiScience2026
Dysregulation of neuronal androgen receptor signaling by divergent collaborative transcription factors in Alzheimer's disease.
Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The transcriptional mechanisms through which androgens and androgen receptor (AR) exert specific effects on human tissues remain elusive. Here, we demonstrated that neuronal cell-specific transcription factors (TFs) may play an important role as epigenetic modifiers that shape the AR cistrome during neuronal activity. The binding of GATA3 to specific regulatory sequences in human neuronal cell models is associated with enhanced AR-mediated transcription. AR-binding sites (ARBSs) are enriched in regions overlapping with super-enhancers (SEs) that encode critical neuronal factors. Furthermore, AR signaling in aged human male brains indicates its role in supporting neural function and declines during the progression of Alzheimer's disease (AD). The expression levels of AR-associated TFs were dysregulated during aging and AD development. Altered expression of TFs may contribute to disruption of AR signaling. Thus, collaborative TFs could contribute to the neuronal androgen response and epigenetic regulation involved in aging and the progression of dementia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.